Hadron Therapy Market Share, Size, Trends, Industry Analysis Report, By Type (Electron Beam, Proton Beam, Neutron Beam, Carbon Ion Beam, Alpha Particle Beam, and Beta Particle Beam); By Application; By End User; By Region; Segment Forecast, 2024 – 2032
- Published Date:Jan-2024
- Pages: 114
- Format: PDF
- Report ID: PM4301
- Base Year: 2023
- Historical Data: 2019 – 2022
The global hadron therapy market was valued at USD 1.73 billion in 2023 and is expected to grow at a CAGR of 11.8% during the forecast period.
The rising awareness among the global population regarding the potential benefits of proton therapy, a drastic increase in the number of healthcare facilities offering or providing innovative hadron therapy, and the exponential rise in the usage of this therapy for patients with benign tumors and tumors near the sensitive areas of the brain, are among the leading factors propelling the global market growth. Besides this, the continuous growth in investments in research & development activities by leading healthcare companies, leading to significant advancements in hadron therapy and making it cost-effective and easily accessible, are further anticipated to generate huge growth opportunities for the market.
To Understand More About this Research: Request a Free Sample Report
- For instance, in March 2022, Novartis announced that the US Food and Drug Administration has approved Pluvicto for the treatment of patients with a certain type of advanced cancer called a prostate-specific membrane. The approval of Pluvicto can significantly improve the survival rates for people with limited treatment options.
Moreover, the growing implementation and development of pencil beam scanning across the world as a more precise form of proton therapy delivers the proton beam in a very narrow pencil-like shape while allowing for highly precise dose delivery. It has gained immense traction as a standard feature in many modern proton therapy facilities worldwide and has led to improved tumor targeting and reduced side effects as well.
However, the high initial cost associated with setting up a hadron therapy facility, including the equipment and infrastructure and limited availability of hadron therapy facilities as compared to traditional or conventional radiation therapy centers, are among the factors projected to hinder growth of the market.
Increasing incidences of cancer cases and improvements in reimbursement policies boost the market growth
The rapidly increasing incidences of several types of cancers across the globe due to factors like the aging population and changes in people's lifestyle and dietary habits, which often require precise treatment solutions like hadron therapy, especially for pediatric cancers and localized tumors, driving the global market growth substantially.
For instance, according to a report published by the American Cancer Society, the number of new cancer cases and deaths caused by cancers in the United States is projected to be 1,958,310 and 609,820, respectively.
Apart from this, continuous improvements in reimbursement policies for hadron therapy by leading healthcare organizations and government authorities have resulted in making the therapy more financially viable for both healthcare providers and patients and will also likely have a positive impact on the market.
The market is primarily segmented based on type, application, end user, and region.
By End User
To Understand the Scope of this Report: Speak to Analyst
By Type Analysis
Alpha particle beam segment accounted for the largest market share in 2022
The alpha particle beam segment accounted for the largest share. The growth of the segment market is highly accelerated by growing awareness among patients as well as healthcare providers about the potential benefits of targeted alpha therapy, along with the continuous rise in the number of patients with cardiac and cancer ailments. For instance, as per a report by the American Heart Association, coronary heart diseases were the leading cause of death, with approximately 41.2% of total deaths in the United States, followed by stroke and other CVDs with 17.3% and 16.8%, respectively.
The proton beam segment is expected to grow at a substantial growth rate during the projected period, mainly due to its greater effectiveness in treating various types of cancer, mainly for those that are located in sensitive or hard-to-reach areas, and its ability to spare health issue, resulting in adoption as a highly preferred choice for many patients and physicians. Besides this, collaborations between healthcare institutions and pharmaceutical companies lead to more research, development, and access to this treatment modality.
By Application Analysis
Pediatric cancer segment held the significant market share in 2022
The pediatric cancer segment held the majority market share in terms of revenue in 2022 and is majorly driven by rising prevalence or incidences of pediatric cancer, leading to an increased need for less toxic and effective treatment options along with the growing research and clinical trials mainly focused on the use of hadron therapy for pediatric cancer. Apart from this, rising support from governments, healthcare organizations, and research institutions towards the development and expansion of advanced hadron treatment facilities has also been pushing the segment market growth over the years.
By End User Analysis
Hospitals segment led the industry with substantial share in 2022
The hospital's segment led the industry market with a substantial share both in terms of revenue and volume in 2022. It will also exhibit the highest growth during the projected period due to the robust presence of innovative and advanced treatment techniques and facilities, including high-tech equipment in the hospitals, and increased investments by both private and government organizations toward the development and expansion of hospital infrastructure.
In addition, hospitals all over the world are heavily investing in cutting-edge technology, including hardon therapy facilities, to remain competitive and offer comprehensive cancer care, which further allows them to stay ahead of their competitors and attract a wider patient base from all over the world.
North America region dominated the global market in 2022
The North America region dominated the global market with a noteworthy share in 2022 and is also anticipated to continue its market dominance over the forecast period, which is significantly driven by the constant increase in the number of cancer cases in the United States and rising investments in hadron therapy technology which have made it more accessible and efficient coupled with the rising government funding and favorable policies supporting the cancer research and creation of advanced treatment options.
The Asia Pacific region is anticipated to emerge as fastest fastest-growing region with a healthy CAGR throughout the study period on account of the region’s substantial improvements in healthcare infrastructure, which includes the establishment of specialized cancer treatment centers and constant surge in medical tourism in some of the Asia Pacific countries, leading to increased demand and need for effective therapy or treatment options.
For instance, according to a report by the Federation of Indian Chambers of Commerce & Industry, India received a total of 650,000 medical tourists in 2022, with a significant increase from 595,000 medical tourists in the year 2019. Not only this, the country has received over 1.4 million medical tourists in the past one year, and the number is continuously increasing.
Key Market Players & Competitive Insights
The hadron therapy market is moderately consolidated in nature with the robust presence of regional and global market players worldwide. Key market companies are extensively focusing on R&D activities to develop and introduce new and more improved therapy for various issues including hadron, and are also opting for several business expansion strategies such as partnerships, collaborations, and new product launches.
Some of the major players operating in the global market include:
- Advanced Oncotherapy
- Danfysik A/S
- Hitachi Ltd.
- IBA Worldwide
- Koninklijke Philips N.V.
- Mevion Medical Systems
- Mitsubishi Electric Corporation
- Optivus Proton Therapy Inc.
- ProNova Solutions LLC
- ProTom International
- Provision Healthcare
- Sumitomo Corporation
- Varian Medical Systems Inc.
- In October 2021, IBA, introduced world’s first online platform that is mainly dedicated to proton therapy. It enables users to share proton therapy-based materials & resources, with the aim to help researchers in the proton therapy.
- In July 2022, Georgia PM, established new Hadron Therapy Centre in Western Georgia’s. They have placed a capsule at the construction site of planned EUR 1 billion, financed by the Cartu Foundation.
Hadron Therapy Market Report Scope
Market size value in 2024
USD 1.93 billion
Revenue forecast in 2032
USD 4.72 billion
11.8% from 2024 – 2032
2019 – 2022
2024 – 2032
Revenue in USD billion and CAGR from 2024 to 2032
By Type, By Application, By End User, By Region
North America, Europe, Asia Pacific, Latin America; Middle East & Africa
Report customization as per your requirements with respect to countries, region and segmentation.
Explore the 2024 market share, size, and revenue growth rate statistics in the field of hadron therapy market, meticulously compiled by Polaris Market Research Industry Reports. This comprehensive analysis encompasses a market forecast outlook extending to 2032, along with an insightful historical overview. Experience the depth of this industry analysis by obtaining a complimentary PDF download of the sample report.
Browse for Our Top Selling Reports
The global hadron therapy market size is expected to reach USD 4.72 billion by 2032
Key players in the market are Mevion Medical Systems, Optivus Proton Therapy, Provision Healthcare
North America contribute notably towards the global hadron therapy market
The global hadron therapy market is expected to grow at a CAGR of 11.8% during the forecast period.
The hadron therapy market report covering key segments are type, application, end user, and region.